- 0
Highlights & Basics
- Asthma in adults presents with recurrent episodes of shortness of breath, chest tightness, wheezing, or coughing.
- Exam typically demonstrates an expiratory wheeze; however, in severe asthma, poor air entry may lead to diminished breath sounds.
- Treatment is stepwise and follows a guideline-based approach to starting, stepping up, and stepping down therapy.
- Patient education, including the provision of an asthma action plan, is key to effective management.
- Some patients may develop progressive, irreversible obstructive lung disease.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Citations
National Institutes of Health; National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma. Aug 2007 [internet publication].[Full Text]
Global Initiative for Asthma. 2024 global strategy for asthma management and prevention. May 2024 [internet publication].[Full Text]
Parsons JP, Hallstrand TS, Mastronarde JG, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2013 May 1;187(9):1016-27.[Abstract][Full Text]
Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC); Cloutier MM, Baptist AP, Blake KV, et al. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020 Dec;146(6):1217-70.[Abstract][Full Text]
1. National Institutes of Health; National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma. Aug 2007 [internet publication].[Full Text]
2. Weiler JM, Brannan JD, Randolph CC, et al. Exercise-induced bronchoconstriction update: 2016. J Allergy Clin Immunol. 2016 Nov;138(5):1292-5.[Abstract][Full Text]
3. Global Initiative for Asthma. 2024 global strategy for asthma management and prevention. May 2024 [internet publication].[Full Text]
4. Lai K, Satia I, Song WJ, et al. Cough and cough hypersensitivity as treatable traits of asthma. Lancet Respir Med. 2023 Jul;11(7):650-62.[Abstract]
5. GBD 2019 Chronic Respiratory Diseases Collaborators. Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019. EClinicalMedicine. 2023 May;59:101936.[Abstract][Full Text]
6. Global Asthma Network. The global asthma report 2022 [internet publication].[Full Text]
7. Centers for Disease Control and Prevention. Asthma Data: most recent national asthma data. Nov 2024 [internet publication].[Full Text]
8. Chowdhury NU, Guntur VP, Newcomb DC, et al. Sex and gender in asthma. Eur Respir Rev. 2021 Nov 17;30(162):210067.[Abstract][Full Text]
9. Centers for Disease Control and prevention. Asthma: most recent national asthma data. May 2023 [internet publication].[Full Text]
10. Centers for Disease Control and Prevention. Asthma as the underlying cause of death. Jul 2023 [internet publication].[Full Text]
11. Grandinetti R, Fainardi V, Caffarelli C, et al. Risk factors affecting development and persistence of preschool wheeezing: consensus document of the Emilia-Romagna Asthma (ERA) study group. J Clin Med. 2022 Nov 4;11(21):6558.[Abstract][Full Text]
12. Ruan Z, Shi Z, Zhang G, et al. Asthma susceptible genes in children: a meta-analysis. Medicine (Baltimore). 2020 Nov 6;99(45):e23051.[Abstract][Full Text]
13. Cardenas A, Fadadu RP, Koppelman GH. Epigenome-wide association studies of allergic disease and the environment. J Allergy Clin Immunol. 2023 Sep;152(3):582-90.[Abstract][Full Text]
14. Ntontsi P, Photiades A, Zervas E, et al. Genetics and epigenetics in asthma. Int J Mol Sci. 2021 Feb 27;22(5):2412.[Abstract][Full Text]
15. Aarafi H, Yadegari A, Dastgheib SA, et al. Association of +1923C > T, -1112C > T and +2044A > G polymorphisms in IL-13 gene with susceptibility to pediatric asthma: a systematic review and meta-analysis. Fetal Pediatr Pathol. 2022 Apr;41(2):259-77.[Abstract]
16. Fan Z, Liu T, Na W. Association of nitric oxide synthase gene polymorphism with asthma: a systematic review and meta-analysis. Clin Respir J. 2023 Jun;17(6):516-26.[Abstract][Full Text]
17. Chen X, Hu J, Li K, et al. Association of the IL-4R Q576R polymorphism with pediatric asthma: a meta-analysis. Afr Health Sci. 2022 Sep;22(3):307-16.[Abstract][Full Text]
18. Kang SW, Kim SK, Han YR, et al. Promoter polymorphism (-308G/A) of tumor necrosis factor-alpha (TNF-alpha) gene and asthma risk: an updated meta-analysis. Genet Test Mol Biomarkers. 2019 Jun;23(6):363-72.[Abstract]
19. Yu X, Wang LW, He Q, et al. Correlation study on beta2-adrenergic receptor gene polymorphisms and asthma susceptibility: evidence based on 57 case-control studies. Eur Rev Med Pharmacol Sci. 2019 May;23(9):3908-25.[Abstract][Full Text]
20. He L, Zhou X, Mo H, et al. The association between vitamin D receptor gene polymorphisms and asthma: a systematic review and meta-analysis. Ann Palliat Med. 2022 Feb;11(2):574-87.[Abstract][Full Text]
21. Restori KH, Srinivasa BT, Ward BJ, et al. Neonatal immunity, respiratory virus infections, and the development of asthma. Front Immunol. 2018;9:1249.[Abstract][Full Text]
22. Singh AM, Busse WW. Asthma exacerbations. 2: aetiology. Thorax. 2006 Sep;61(9):809-16.[Abstract][Full Text]
23. Bobolea I, Hagemann J, Sanak M, et al. Current goals of NSAID-ERD management: patient-centered approaches involving NSAID desensitization with and without biologics. J Allergy Clin Immunol Pract. 2024 Nov;12(11):2934-44.[Abstract][Full Text]
24. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J. 2000 Sep;16(3):432-6.[Abstract][Full Text]
25. Morales DR, Guthrie B, Lipworth BJ, et al. NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. Allergy. 2015 Jul;70(7):828-35.[Abstract]
26. Pietinalho A, Pelkonen A, Rytilä P. Linkage between smoking and asthma. Allergy. 2009 Dec;64(12):1722-7.[Abstract][Full Text]
27. Ferreira MA, Vonk JM, Baurecht H, et al. Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. Nat Genet. 2017 Dec;49(12):1752-57.[Abstract]
28. Joshi D, Duong M, Kirkland S, et al. Impact of electronic cigarette ever use on lung function in adults aged 45-85: a cross-sectional analysis from the Canadian Longitudinal Study on Aging. BMJ Open. 2021 Oct 27;11(10):e051519.[Abstract][Full Text]
29. Wills TA, Soneji SS, Choi K, et al. E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies. Eur Respir J. 2021 Jan;57(1):1901815.[Abstract][Full Text]
30. Rose JJ, Krishnan-Sarin S, Exil VJ, et al. Cardiopulmonary impact of electronic cigarettes and vaping products: a scientific statement from the American Heart Association. Circulation. 2023 Aug 22;148(8):703-28.[Abstract]
31. Boogaard H, Patton AP, Atkinson RW, et al. Long-term exposure to traffic-related air pollution and selected health outcomes: A systematic review and meta-analysis. Environ Int. 2022 Jun;164:107262.[Abstract][Full Text]
32. Brunekreef B, Strak M, Chen J, et al. Mortality and morbidity effects of long-term exposure to low-level PM(2.5), BC, NO(2), and O(3): an analysis of European cohorts in the ELAPSE project. Res Rep Health Eff Inst. 2021 Sep;2021(208):1-127.[Abstract][Full Text]
33. Orellano P, Quaranta N, Reynoso J, et al. Effect of outdoor air pollution on asthma exacerbations in children and adults: systematic review and multilevel meta-analysis. PLoS One. 2017 Mar 20;12(3):e0174050.[Abstract][Full Text]
34. Paterson CA, Sharpe RA, Taylor T, et al. Indoor PM2.5, VOCs and asthma outcomes: a systematic review in adults and their home environments. Environ Res. 2021 Nov;202:111631.[Abstract][Full Text]
35. Nassikas NJ, McCormack MC, Ewart G, et al. Indoor air sources of outdoor air pollution: health consequences, policy, and recommendations: an official American Thoracic Society workshop report. Ann Am Thorac Soc. 2024 Mar;21(3):365-76.[Abstract][Full Text]
36. Maung TZ, Bishop JE, Holt E, et al. Indoor air pollution and the health of vulnerable groups: a systematic review focused on particulate matter (PM), volatile organic compounds (VOCs) and their effects on children and people with pre-existing lung disease. Int J Environ Res Public Health. 2022 Jul 19;19(14):8752.[Abstract][Full Text]
37. Liu N, Bu Z, Liu W, et al. Health effects of exposure to indoor volatile organic compounds from 1980 to 2017: a systematic review and meta-analysis. Indoor Air. 2022 May;32(5):e13038.[Abstract]
38. Sharma V, Cowan DC. Obesity, inflammation, and severe asthma: an update. Curr Allergy Asthma Rep. 2021 Dec 18;21(12):46.[Abstract][Full Text]
39. Miethe S, Karsonova A, Karaulov A, et al. Obesity and asthma. J Allergy Clin Immunol. 2020 Oct;146(4):685-93.[Abstract][Full Text]
40. Xie L, Chandrasekhar A, DeSantis SM, et al. Discontinuation and reduction of asthma medications after metabolic and bariatric surgery: a systematic review and meta-analysis. Obes Rev. 2023 Feb;24(2):e13527.[Abstract]
41. Oosterholt S, Pavord ID, Brusselle G, et al. Modelling ASthma TrEatment Responses (MASTER): effect of individual patient characteristics on the risk of exacerbation in moderate or severe asthma: a time-to-event analysis of randomized clinical trials. Br J Clin Pharmacol. 2023 Nov;89(11):3273-90.[Abstract][Full Text]
42. Thompson CA, Eslick SR, Berthon BS, et al. Asthma medication use in obese and healthy weight asthma: systematic review/meta-analysis. Eur Respir J. 2021 Mar;57(3):2000612.[Abstract][Full Text]
43. Scott HA, Ng SH, McLoughlin RF, et al. Effect of obesity on airway and systemic inflammation in adults with asthma: a systematic review and meta-analysis. Thorax. 2023 Oct;78(10):957-65.[Abstract]
44. Burbank AJ, Hernandez ML, Jefferson A, et al. Environmental justice and allergic disease: a work group report of the AAAAI Environmental Exposure and Respiratory Health Committee and the Diversity, Equity and Inclusion Committee. J Allergy Clin Immunol. 2023 Mar;151(3):656-70.[Abstract][Full Text]
45. van der Wiel E, ten Hacken NH, Postma DS, et al. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review. J Allergy Clin Immunol. 2013 Mar;131(3):646-57.[Abstract]
46. Saikumar Jayalatha AK, Hesse L, Ketelaar ME, et al. The central role of IL-33/IL-1RL1 pathway in asthma: from pathogenesis to intervention. Pharmacol Ther. 2021 Sep;225:107847.[Abstract][Full Text]
47. Han YY, Zhang X, Wang J, et al. Multidimensional assessment of asthma identifies clinically relevant phenotype overlap: a cross-sectional study. J Allergy Clin Immunol Pract. 2021 Jan;9(1):349-62.e18.[Abstract]
48. Luo W, Hu J, Xu W, et al. Distinct spatial and temporal roles for Th1, Th2, and Th17 cells in asthma. Front Immunol. 2022;13:974066.[Abstract][Full Text]
49. Yue M, Gaietto K, Han YY, et al. Transcriptomic profiles in nasal epithelium and asthma endotypes in Youth. JAMA. 2025 Jan 28;333(4):307-18.[Abstract][Full Text]
50. Seys SF, Long MB. The quest for biomarkers in asthma: challenging the T2 versus non-T2 paradigm. Eur Respir J. 2022 Feb 17;59(2):2102669. [Abstract][Full Text]
51. Ballow M. Biologic immune modifiers: trials and tribulations - are we there yet? J Allergy Clin Immunol. 2006 Dec;118(6):1209-15.[Abstract]
52. Wark PA, Gibson PG. Asthma exacerbations. 3: pathogenesis. Thorax. 2006 Oct;61(10):909-15.[Abstract][Full Text]
53. Boyce JA. Asthma 2005-2006: bench to bedside. J Allergy Clin Immunol. 2006 Sep;118(3):582-6.[Abstract]
54. Cockcroft DW, Davis BE. Mechanisms of airway hyperresponsiveness. J Allergy Clin Immunol. 2006 Sep;118(3):551-9.[Abstract]
55. Kuruvilla ME, Vanijcharoenkarn K, Shih JA, et al. Epidemiology and risk factors for asthma. Respir Med. 2019 Mar;149:16-22.[Full Text]
56. Koefoed HJL, Zwitserloot AM, Vonk JM, et al. Asthma, bronchial hyperresponsiveness, allergy and lung function development until early adulthood: a systematic literature review. Pediatr Allergy Immunol. 2021 Aug;32(6):1238-54.[Abstract][Full Text]
57. Boogaard H, Patton AP, Atkinson RW, et al. Long-term exposure to traffic-related air pollution and selected health outcomes: a systematic review and meta-analysis. Environ Int. 2022 Jun;164:107262.[Abstract][Full Text]
58. Huang J, Yang X, Fan F, et al. Outdoor air pollution and the risk of asthma exacerbations in single lag0 and lag1 exposure patterns: a systematic review and meta-analysis. J Asthma. 2022 Nov;59(11):2322-39.[Abstract][Full Text]
59. Ravnborg N, Ambikaibalan D, Agnihotri G, et al. Prevalence of asthma in patients with atopic dermatitis: a systematic review and meta-analysis. J Am Acad Dermatol. 2021 Feb;84(2):471-8.[Abstract]
60. Gabryszewski SJ, Hill DA. One march, many paths: insights into allergic march trajectories. Ann Allergy Asthma Immunol. 2021 Sep;127(3):293-300.[Abstract]
61. Wu T, Jahangir MR, Mensink-Bout SM, et al. Visceral adiposity and respiratory outcomes in children and adults: a systematic review. Int J Obes (Lond). 2022 Jun;46(6):1083-100.[Abstract][Full Text]
62. Zhu Z, Guo Y, Shi H, et al. Shared genetic and experimental links between obesity-related traits and asthma subtypes in UK Biobank. J Allergy Clin Immunol. 2020 Feb;145(2):537-49.[Abstract][Full Text]
63. Shore SA. Obesity and asthma: possible mechanisms. J Allergy Clin Immunol. 2008 May;121(5):1087-93.[Abstract]
64. King GG, Brown NJ, Diba C, et al. The effects of body weight on airway calibre. Eur Respir J. 2005 May;25(5):896-901.[Abstract][Full Text]
65. Polosa R, Thomson NC. Smoking and asthma: dangerous liaisons. Eur Respir J. 2013 Mar;41(3):716-26.[Abstract][Full Text]
66. Jonas A. Impact of vaping on respiratory health. BMJ. 2022 Jul 18;378:e065997.[Abstract]
67. Bradford LE, Rebuli ME, Ring BJ, et al. Danger in the vapor? ECMO for adolescents with status asthmaticus after vaping. J Asthma. 2020 Nov;57(11):1168-72.[Abstract]
68. Wold LE, Tarran R, Crotty Alexander LE, et al. Cardiopulmonary consequences of vaping in adolescents: a scientific statement from the American Heart Association. Circ Res. 2022 Jul 22;131(3):e70-82.[Abstract][Full Text]
69. Tackett AP, Urman R, Barrington-Trimis J, et al. Prospective study of e-cigarette use and respiratory symptoms in adolescents and young adults. Thorax. 2024 Jan 18;79(2):163-8.[Abstract][Full Text]
70. Pérez A, Valencia S, Jani PP, et al. Use of electronic nicotine delivery systems and age of asthma onset among US adults and youths. JAMA Netw Open. 2024 May 1;7(5):e2410740.[Abstract][Full Text]
71. Heikkilä P, Korppi M, Ruotsalainen M, et al. Viral wheezing in early childhood as a risk factor for asthma in young adulthood: a prospective long-term cohort study. Health Sci Rep. 2022 Mar;5(2):e538.[Abstract][Full Text]
72. Feddema JJ, Claassen E. Prevalence of viral respiratory infections amongst asthmatics: results of a meta-regression analysis. Respir Med. 2020 Nov;173:106020.[Abstract][Full Text]
73. Laidlaw TM, Mullol J, Woessner KM, et al. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1133-41.[Abstract][Full Text]
74. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy. 2016;9:45-53.[Abstract][Full Text]
75. Redmond C, Akinoso-Imran AQ, Heaney LG, et al. Socioeconomic disparities in asthma health care utilization, exacerbations, and mortality: a systematic review and meta-analysis. J Allergy Clin Immunol. 2022 May;149(5):1617-27.[Abstract][Full Text]
76. Paoletti G, Melone G, Ferri S, et al. Gastroesophageal reflux and asthma: when, how, and why. Curr Opin Allergy Clin Immunol. 2021 Feb 1;21(1):52-58.[Abstract]
77. Cantarutti A, Barbiellini Amidei C, Valsecchi C, et al. Association of treated and untreated gastroesophageal reflux disease in the first year of life with the subsequent development of asthma. Int J Environ Res Public Health. 2021 Sep 13;18(18):9633.[Abstract]
78. Rogers L. Role of sleep apnea and gastroesophageal reflux in aevere asthma. Immunol Allergy Clin North Am. 2016 Aug;36(3):461-71.[Abstract]
79. Kopsaftis Z, Yap HS, Tin KS, et al. Pharmacological and surgical interventions for the treatment of gastro-oesophageal reflux in adults and children with asthma. Cochrane Database Syst Rev. 2021 May 17;5:CD001496.[Abstract][Full Text]
80. Zheng Z, Luo Y, Li J, et al. Randomised trials of proton pump inhibitors for gastro-oesophageal reflux disease in patients with asthma: an updated systematic review and meta-analysis. BMJ Open. 2021 Aug 10;11(8):e043860.[Abstract][Full Text]
81. Prasad B, Nyenhuis SM, Imayama I, et al. Asthma and abstructive sleep apnea overlap: what has the evidence taught us? Am J Respir Crit Care Med. 2020 Jun 1;201(11):1345-57.[Abstract][Full Text]
82. Kong DL, Qin Z, Shen H, et al. Association of obstructive sleep apnea with asthma: a meta-analysis. Sci Rep. 2017 Jun 22;7(1):4088.[Abstract][Full Text]
83. Toelle BG, Xuan W, Peat JK, et al. Childhood factors that predict asthma in young adulthood. Eur Respir J. 2004 Jan;23(1):66-70.[Abstract][Full Text]
84. Crump C, Sundquist J, Sundquist K. Preterm or early term birth and long-term risk of asthma into midadulthood: a national cohort and cosibling study. Thorax. 2023 Jul;78(7):653-60.[Abstract][Full Text]
85. Pulakka A, Risnes K, Metsälä J, et al. Preterm birth and asthma and COPD in adulthood: a nationwide register study from two Nordic countries. Eur Respir J. 2023 Jun 22;61(6):2201763.[Abstract][Full Text]
86. Htet TD, Teede HJ, de Courten B, et al. Asthma in reproductive-aged women with polycystic ovary syndrome and association with obesity. Eur Respir J. 2017 May 1;49(5):1601334.[Abstract][Full Text]
87. Sun H, Li D, Jiao J, et al. A potential link between polycystic ovary syndrome and asthma: a meta-analysis. Reprod Sci. 2022 Jan;29(1):312-9.[Abstract]
88. Xu Y, Zhou ZY, Pan JX, et al. Associations between asthma and polycystic ovary syndrome: current perspectives. Front Endocrinol (Lausanne). 2022;13:936948.[Abstract][Full Text]
89. Juber NF, Abdulle A, AlJunaibi A, et al. Association between pediatric asthma and adult polycystic ovarian syndrome (PCOS): a cross-sectional analysis of the UAE healthy future Study (UAEHFS). Front Endocrinol (Lausanne). 2023;14:1022272.[Abstract][Full Text]
90. Cassim R, Russell MA, Lodge CJ, et al. The role of circulating 25 hydroxyvitamin D in asthma: a systematic review. Allergy. 2015 Apr;70(4):339-54.[Abstract][Full Text]
91. Williamson A, Martineau AR, Sheikh A, et al. Vitamin D for the management of asthma. Cochrane Database Syst Rev. 2023 Feb 6;2(2):CD011511.[Abstract][Full Text]
92. Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data. Lancet Respir Med. 2017 Nov;5(11):881-90.[Abstract][Full Text]
93. Wang Y, Wang J, Chen L, et al. Efficacy of vitamin D supplementation on COPD and asthma control: a systematic review and meta-analysis. J Glob Health. 2022 Dec 16;12:04100.[Abstract][Full Text]
94. El Abd A, Dasari H, Dodin P, et al. The effects of vitamin D supplementation on inflammatory biomarkers in patients with asthma: a systematic review and meta-analysis of randomized controlled trials. Front Immunol. 2024;15:1335968.[Abstract][Full Text]
95. Mocelin HT, Fischer GB, Bush A. Adverse early-life environmental exposures and their repercussions on adult respiratory health. J Pediatr (Rio J). 2022 Mar-Apr;98 Suppl 1(suppl 1):S86-S95.[Abstract][Full Text]
96. Litonjua AA, Carey VJ, Laranjo N, et al. Six-year follow-up of a trial of antenatal vitamin D for asthma reduction. N Engl J Med. 2020 Feb 6;382(6):525-33.[Abstract][Full Text]
97. Gupta S, Thériault G. Do not diagnose or routinely treat asthma or chronic obstructive pulmonary disease without pulmonary function testing. BMJ. 2023 Mar 20;380:e072834.
98. Louis R, Satia I, Ojanguren I, et al. European Respiratory Society guidelines for the diagnosis of asthma in adults. Eur Respir J. 2022 Feb 15;2101585 [Epub ahead of print].[Abstract][Full Text]
99. Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022 Jul 13;60(1):2101499.[Abstract][Full Text]
100. Parsons JP, Hallstrand TS, Mastronarde JG, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2013 May 1;187(9):1016-27.[Abstract][Full Text]
101. British Thoracic Society. BTS clinical statement: assessment and management of respiratory problems in athletic individuals. Apr 2022 [internet publication].[Full Text]
102. Cockcroft DD. Direct and indirect challenges in the clinical assessment of asthma. Ann Allergy Asthma Immunol. 2009 Nov;103(5):363-9.[Abstract]
103. Lee J, Song JU. Diagnostic comparison of methacholine and mannitol bronchial challenge tests for identifying bronchial hyperresponsiveness in asthma: a systematic review and meta-analysis. J Asthma. 2021 Jul;58(7):883-91.[Abstract][Full Text]
104. Guida G, Bagnasco D, Carriero V, et al. Critical evaluation of asthma biomarkers in clinical practice. Front Med (Lausanne). 2022;9:969243.[Abstract][Full Text]
105. Agache I, Akdis CA, Akdis M, et al. EAACI biologicals guidelines: recommendations for severe asthma. Allergy. 2021 Jan;76(1):14-44.[Abstract][Full Text]
106. Oppenheimer J, Hoyte FCL, Phipatanakul W, et al. Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. Ann Allergy Asthma Immunol. 2022 Aug;129(2):169-80.[Abstract][Full Text]
107. Guida G, Bertolini F, Carriero V, et al. Reliability of total serum IgE levels to define type 2 high and low asthma phenotypes. J Clin Med. 2023 Aug 22;12(17):5447.[Abstract][Full Text]
108. Wang E, Wechsler ME. A rational approach to compare and select biologic therapeutics in asthma. Ann Allergy Asthma Immunol. 2022 Apr;128(4):379-89.[Abstract][Full Text]
109. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021 Jul;9(7):2680-8.e7.[Abstract][Full Text]
110. Menzies-Gow A, Mansur AH, Brightling CE. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020 Mar;55(3):1901633.[Abstract][Full Text]
111. Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC); Cloutier MM, Baptist AP, Blake KV, et al. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020 Dec;146(6):1217-70.[Abstract][Full Text]
112. Khatri SB, Iaccarino JM, Barochia A, et al. Use of fractional exhaled nitric oxide to guide the treatment of asthma: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2021 Nov 15;204(10):e97-109.[Abstract][Full Text]
113. Alahmadi F, Peel A, Keevil B, et al. Assessment of adherence to corticosteroids in asthma by drug monitoring or fractional exhaled nitric oxide: a literature review. Clin Exp Allergy. 2021 Jan;51(1):49-62.[Abstract][Full Text]
114. Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Respir Med. 2015 Apr;3(4):290-300.[Abstract]
115. Petsky HL, Kew KM, Turner C, et al. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev. 2016 Sep 1;(9):CD011440.[Abstract][Full Text]
116. Petsky HL, Li A, Chang AB. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev. 2017 Aug 24;(8):CD005603.[Abstract][Full Text]
117. Benson VS, Hartl S, Barnes N, et al. Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis. Eur Respir J. 2022 Jan 13;59(1):2004590.[Abstract][Full Text]
118. Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet. 2011 Sep 10;378(9795):983-90.[Abstract]
119. Honkoop PJ, Loijmans RJ, Termeer EH, et al; Asthma Control Cost-Utility Randomized Trial Evaluation (ACCURATE) Study Group. Symptom-and fraction of exhaled nitric oxide-driven strategies for asthma control: a cluster-randomized trial in primary care. J Allergy Clin Immunol. 2015 Mar;135(3):682-8.[Abstract]
120. American College of Radiology. ACR appropriateness criteria: adult. Chronic dyspnea. Unclear etiology. Initial imaging. 2024 [internet publication].[Full Text]
121. Castagnoli R, Licari A, Brambilla I, et al. An update on the role of chronic rhinosinusitis with nasal polyps as a co-morbidity in severe asthma. Expert Rev Respir Med. 2020 Dec;14(12):1197-205.[Abstract][Full Text]
122. Mullol J, Maldonado M, Castillo JA, et al. Management of united airway disease focused on patients with asthma and chronic rhinosinusitis with nasal polyps: a systematic review. J Allergy Clin Immunol Pract. 2022 Sep;10(9):2438-47.e9.[Abstract]
123. Backer V, Cardell LO, Lehtimäki L, et al. Multidisciplinary approaches to identifying and managing global airways disease: expert recommendations based on qualitative discussions. Front Allergy. 2023;4:1052386.[Abstract]
124. Pollart SM, Compton RM, Elward KS. Management of acute asthma exacerbations. Am Fam Physician. 2011 Jul 1;84(1):40-7.[Abstract][Full Text]
125. National Institute for Health and Care Excellence. Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN). Nov 2024 [internet publication].[Full Text]
126. Vandenplas O, Suojalehto H, Cullinan P. Diagnosing occupational asthma. Clin Exp Allergy. 2017 Jan;47(1):6-18.[Abstract][Full Text]
127. Asamoah-Boaheng M, Farrell J, Osei Bonsu K, et al. Examining risk factors accelerating time-to-chronic obstructive pulmonary disease (COPD) diagnosis among asthma patients. COPD. 2022;19(1):47-56.[Abstract][Full Text]
128. U.S. Food and Drug Administration. Drug safety communication: FDA requires boxed warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. March 2020 [internet publication].[Full Text]
129. Lan G, Huang C, Liu Y, et al. How does comorbid bronchiectasis affect asthmatic patients? A meta-analysis. J Asthma. 2021 Oct;58(10):1314-28.[Abstract]
130. Carden KA, Boiselle PM, Waltz DA, et al. Tracheomalacia and tracheobronchomalacia in children and adults. An in-depth review. Chest. 2005 Mar;127(3):984-1005.[Abstract][Full Text]
131. Lee KS, Sun MRM, Ernst A, et al. Comparison of dynamic expiratory CT with bronchoscopy for diagnosing airway malacia: a pilot evaluation. Chest. 2007 Mar;131(3):758-64.[Abstract][Full Text]
132. Mohan A, Lugogo NL, Hanania NA, et al. Questions in mild asthma: an official American Thoracic Society research statement. Am J Respir Crit Care Med. 2023 Jun 1;207(11):e77-96.[Abstract]
133. Canadian Thoracic Society. Canadian Thoracic Society 2021 guideline update: diagnosis and management of asthma in preschoolers, children and adults. Aug 2021 [internet publication].[Full Text]
134. Canadian Thoracic Society. Recognition and management of severe asthma: a Canadian Thoracic Society position statement. 2017 [internet publication].[Full Text]
135. Global Initiative for Asthma. Diagnosis and management of difficult-to-treat & severe asthma. 2023 [internet publication].[Full Text]
136. Al-Moamary MS, Alhaider SA, Allehebi R, et al. The Saudi initiative for asthma - 2024 update: guidelines for the diagnosis and management of asthma in adults and children. Ann Thorac Med. 2024 Jan-Mar;19(1):1-55.[Abstract][Full Text]
137. Niimi A, Fukunaga K, Taniguchi M, et al. Executive summary: Japanese guidelines for adult asthma (JGL) 2021. Allergol Int. 2023 Apr;72(2):207-26.[Abstract][Full Text]
138. Kawamatawong T, Sangasapaviriya A, Saiphoklang N, et al. Guidelines for the management of asthma in adults: evidence and recommendations. Asian Pac J Allergy Immunol. 2022 Mar;40(1):1-21.[Abstract][Full Text]
139. National Asthma Council. Australian asthma handbook: the national guidelines for health professionals. April 2022 [internet publication].[Full Text]
140. National Institute for Health and Care Excellence. Asthma pathway (BTS, NICE, SIGN). Nov 2024 [internet publication].[Full Text]
141. Hodkinson A, Bower P, Grigoroglou C, et al. Self-management interventions to reduce healthcare use and improve quality of life among patients with asthma: systematic review and network meta-analysis. BMJ. 2020 Aug 18;370:m2521.[Abstract][Full Text]
142. Ahmad S, Kew KM, Normansell R. Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids. Cochrane Database Syst Rev. 2015 Jun 19;(6):CD011306.[Abstract][Full Text]
143. Shang W, Wang G, Wang Y, et al. The safety of long-term use of inhaled corticosteroids in patients with asthma: a systematic review and meta-analysis. Clin Immunol. 2022 Mar;236:108960.[Abstract]
144. Oba Y, Anwer S, Patel T, et al. Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 Aug 21;8(8):CD013797.[Abstract][Full Text]
145. Crossingham I, Turner S, Ramakrishnan S, et al. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma. Cochrane Database Syst Rev. 2021 May 4;(5):CD013518.[Abstract][Full Text]
146. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respir Med. 2021 Feb;9(2):149-58.[Abstract]
147. Nwaru BI, Ekström M, Hasvold P, et al. Overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020 Apr;55(4):1901872.[Abstract][Full Text]
148. Rogliani P, Beasley R, Cazzola M, et al. SMART for the treatment of asthma: a network meta-analysis of real-world evidence. Respir Med. 2021 Nov;188:106611.[Abstract][Full Text]
149. Rogliani P, Ritondo BL, Ora J, et al. SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. Eur Respir J. 2020 Sep;56(3):2000625.[Abstract][Full Text]
150. Janjua S, Schmidt S, Ferrer M, et al. Inhaled steroids with and without regular formoterol for asthma: serious adverse events. Cochrane Database Syst Rev. 2019 Sep 25;(9):CD006924.[Abstract][Full Text]
151. Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007 May 17;356(20):2040-52.[Abstract][Full Text]
152. Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. 2011 Feb 19;377(9766):650-7.[Abstract]
153. Calhoun WJ, Ameredes BT, King TS, et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA. 2012 Sep 12;308(10):987-97.[Abstract][Full Text]
154. Sumino K, Bacharier LB, Taylor J, et al. A pragmatic trial of symptom-based inhaled corticosteroid use in African-American children with mild asthma. J Allergy Clin Immunol Pract. 2020 Jan;8(1):176-85.[Abstract][Full Text]
155. Hu Y, Kung J, Galatis D, et al. Short acting beta agonist use associated with increased mortality and morbidity in asthma patients: a systematic review and meta-analysis. J Pharm Pharm Sci. 2022;25:193-200.[Abstract][Full Text]
156. Stanford RH, Shah MB, D'Souza AO, et al. Short-acting beta-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012 Dec;109(6):403-7.[Abstract]
157. Bloom CI, Cabrera C, Arnetorp S, et al. Asthma-related health outcomes associated with short-acting beta2-agonist inhaler use: an observational UK study as part of the SABINA global program. Adv Ther. 2020 Oct;37(10):4190-208.[Abstract][Full Text]
158. Amin S, Soliman M, McIvor A, et al. Usage patterns of short-acting beta2-agonists and inhaled corticosteroids in asthma: a targeted literature review. J Allergy Clin Immunol Pract. 2020 Sep;8(8):2556-64.[Abstract]
159. Kaplan AG, Correia-de-Sousa J, McIvor A, et al. Global quality statements on reliever use in asthma in adults and children older than 5 years of age. Adv Ther. 2021 Mar;38(3):1382-96.[Abstract][Full Text]
160. Lugogo N, O'Connor M, George M, et al. Expert consensus on SABA use for asthma clinical decision-making: a delphi approach. Curr Allergy Asthma Rep. 2023 Nov;23(11):621-34.[Abstract][Full Text]
161. Bateman ED, Reddel HK, O'Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018 May 17;378(20):1877-87.[Abstract][Full Text]
162. Ni Chroinin M, Greenstone I, Lasserson TJ, et al. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD005307.[Abstract][Full Text]
163. Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD007313.[Abstract][Full Text]
164. Kew KM, Karner C, Mindus SM, et al. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013 Dec 16;(12):CD009019.[Abstract][Full Text]
165. Papi A, Corradi M, Pigeon-Francisco C, et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med. 2013 Mar;1(1):23-31.[Abstract]
166. Patel M, Pilcher J, Pritchard A, et al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med. 2013 Mar;1(1):32-42.[Abstract]
167. Bateman ED, Harrison TW, Quirce S, et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res. 2011 Apr 4;12:38.[Abstract][Full Text]
168. Jorup C, Lythgoe D, Bisgaard H. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma. Eur Respir J. 2018 Jan;51(1):1701688.[Abstract][Full Text]
169. Demoly P, Louis R, Søes-Petersen U, et al. Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. Respir Med. 2009 Nov;103(11):1623-32.[Abstract][Full Text]
170. O'Shea O, Stovold E, Cates CJ. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2021 Apr 14;4:CD007694.[Abstract][Full Text]
171. Papi A, Chipps BE, Beasley R, et al. Albuterol-budesonide fixed-dose combination rescue inhaler for asthma. N Engl J Med. 2022 Jun 2;386(22):2071-83.[Abstract]
172. Beasley R, Harrison T, Peterson S, et al. Evaluation of budesonide-formoterol for maintenance and reliever therapy among patients with poorly controlled asthma: a systematic review and meta-analysis. JAMA Netw Open. 2022 Mar 1;5(3):e220615.[Abstract][Full Text]
173. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2012 May 16;(5):CD002314.[Abstract][Full Text]
174. O'Byrne PM, Naya IP, Kallen A, et al. Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control. Chest. 2008 Dec;134(6):1192-9.[Abstract][Full Text]
175. Chalitsios CV, Shaw DE, McKeever TM. Corticosteroids and bone health in people with asthma: a systematic review and meta-analysis. Respir Med. 2021 May;181:106374.[Abstract][Full Text]
176. Sobieraj DM, Baker WL, Nguyen E, et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: a systematic review and meta-analysis. JAMA. 2018 Apr 10;319(14):1473-84.[Abstract][Full Text]
177. Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016 Jan 21;(1):CD011721.[Abstract][Full Text]
178. Kim LHY, Saleh C, Whalen-Browne A, et al. Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: a systematic review and meta-analysis. JAMA. 2021 Jun 22;325(24):2466-79.[Abstract]
179. Rogliani P, Ritondo BL, Calzetta L. Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies. Eur Respir J. 2021 Sep 2;58(3):2004233.[Abstract][Full Text]
180. Agusti A, Fabbri L, Lahousse L, et al. Single inhaler triple therapy (SITT) in asthma: systematic review and practice implications. Allergy. 2022 Apr;77(4):1105-113.[Abstract][Full Text]
181. Oba Y, Anwer S, Maduke T, et al. Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2022 Dec 6;12(12):CD013799.[Abstract][Full Text]
182. Muiser S, Gosens R, van den Berge M, et al. Understanding the role of long-acting muscarinic antagonists in asthma treatment. Ann Allergy Asthma Immunol. 2022 Apr;128(4):352-60.[Abstract][Full Text]
183. Menzies-Gow A, Moore WC, Wechsler ME. Difficult-to-control asthma management in adults. J Allergy Clin Immunol Pract. 2022 Feb;10(2):378-84.[Abstract]
184. Volmer T, Effenberger T, Trautner C, et al. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018 Oct;52(4):1800703.[Abstract][Full Text]
185. Cataldo D, Louis R, Michils A, et al. Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways. J Asthma. 2021 Apr;58(4):448-58.[Abstract][Full Text]
186. Hiles SA, McDonald VM, Guilhermino M, et al. Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. Eur Respir J. 2019 Nov;54(5):1901381.[Abstract][Full Text]
187. Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Aug 12;390(10095):659-68.[Abstract]
188. Thomas D, McDonald VM, Stevens S, et al. Effect of azithromycin on asthma remission in adults with persistent uncontrolled asthma: a secondary analysis of a randomized, double-anonymized, placebo-controlled trial. Chest. 2024 Aug;166(2):262-70.[Abstract][Full Text]
189. Undela K, Goldsmith L, Kew KM, et al. Macrolides versus placebo for chronic asthma. Cochrane Database Syst Rev. 2021 Nov 22;11:CD002997.[Abstract][Full Text]
190. Zaroff JG, Cheetham TC, Palmetto N, et al. Association of azithromycin use with cardiovascular mortality. JAMA Netw Open. 2020 Jun 1;3(6):e208199.[Abstract][Full Text]
191. Bourdin A, Husereau D, Molinari N, et al. Matching-adjusted comparison of oral corticosteroid reduction in asthma: systematic review of biologics. Clin Exp Allergy. 2020 Apr;50(4):442-52.[Abstract][Full Text]
192. Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 May;75(5):1023-42.[Abstract][Full Text]
193. Calzetta L, Aiello M, Frizzelli A, et al. Oral corticosteroids dependence and biologic drugs in severe asthma: myths or facts? A systematic review of real-world evidence. Int J Mol Sci. 2021 Jul 1;22(13):7132.[Abstract][Full Text]
194. Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022 Jan 13;386(2):157-71.
195. Gallagher A, Edwards M, Nair P, et al. Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma. Cochrane Database Syst Rev. 2021 Oct 19;10:CD012929.[Abstract][Full Text]
196. Agache I, Rocha C, Beltran J, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: a systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 May;75(5):1043-57.[Abstract][Full Text]
197. Jackson K, Bahna SL. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases. Expert Rev Clin Immunol. 2020 Mar;16(3):311-9.[Abstract][Full Text]
198. Tejwani V, Chang HY, Tran AP, et al. The asthma evidence base: a call for core outcomes in interventional trials. J Asthma. 2021 Jul;58(7):855-64.[Abstract][Full Text]
199. Edris A, Lahousse L. Monoclonal antibodies in type 2 asthma: an updated network meta-analysis. Minerva Med. 2021 Oct;112(5):573-81.[Abstract][Full Text]
200. Prætorius K, Henriksen DP, Schmid JM, et al. Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma. ERJ Open Res. 2021 Aug 31;7(3):00306-2021.[Abstract][Full Text]
201. Saco T, Ugalde IC, Cardet JC, et al. Strategies for choosing a biologic for your patient with allergy or asthma. Ann Allergy Asthma Immunol. 2021 Dec;127(6):627-37.[Abstract][Full Text]
202. Charles D, Shanley J, Temple SN, et al. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis. Clin Exp Allergy. 2022 May;52(5):616-27.[Abstract][Full Text]
203. Akenroye A, Lassiter G, Jackson JW, et al. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis. J Allergy Clin Immunol. 2022 Nov;150(5):1097-105.e12.[Abstract][Full Text]
204. MacDonald KM, Kavati A, Ortiz B, et al. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Rev Clin Immunol. 2019 May;15(5):553-69.[Abstract][Full Text]
205. Faulkner KM, MacDonald K, Abraham I, et al. 'Real-world' effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis. Expert Rev Clin Immunol. 2021 Jan;17(1):73-83.[Abstract]
206. Colombo GL, Di Matteo S, Martinotti C, et al. Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619841350.[Abstract][Full Text]
207. Bousquet J, Humbert M, Gibson PG, et al. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol Pract. 2021 Jul;9(7):2702-14.[Abstract][Full Text]
208. Li Y, Li X, Zhang B, et al. Predictive biomarkers for response to omalizumab in patients with severe allergic asthma: a meta-analysis. Expert Rev Respir Med. 2022 Sep;16(9):1023-33.[Abstract]
209. Humbert M, Taillé C, Mala L, et al. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J. 2018 May 10;51(5):1702523.[Abstract][Full Text]
210. Busse WW. Are peripheral blood eosinophil counts a guideline for omalizumab treatment? STELLAIR says no!. Eur Respir J. 2018 May 10;51(5):1800730.[Full Text]
211. Just J, Thonnelier C, Bourgoin-Heck M, et al. Omalizumab effectiveness in severe allergic asthma with multiple allergic comorbidities: a post-hoc analysis of the STELLAIR Study. J Asthma Allergy. 2021;14:1129-38.[Abstract][Full Text]
212. Farne HA, Wilson A, Milan S, et al. Anti-IL-5 therapies for asthma. Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD010834.[Abstract][Full Text]
213. Ortega H, Menzies-Gow A, Llanos JP, et al. Rapid and consistent improvements in morning PEF in patients with severe eosinophilic asthma treated with mepolizumab. Adv Ther. 2018 Jul;35(7):1059-68.[Abstract][Full Text]
214. Israel E, Canonica GW, Brusselle G, et al. Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review. J Asthma. 2022 Nov;59(11):2201-17.[Abstract][Full Text]
215. Albers FC, Bratton DJ, Gunsoy NB, et al. Mepolizumab improves work productivity, activity limitation, symptoms, and rescue medication use in severe eosinophilic asthma. Clin Respir J. 2022 Mar;16(3):252-8.[Abstract][Full Text]
216. Albers FC, Papi A, Taillé C, et al. Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA. Respir Res. 2019 Jul 30;20(1):169.[Abstract][Full Text]
217. Lugogo N, Liu MC, Pavord I, et al. Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: a meta-analysis. J Allergy Clin Immunol Pract. 2021 Sep;9(9):3506-9.e3.[Abstract][Full Text]
218. Gerday S, Graff S, Moermans C, et al. Super-responders to anti-IL-5/anti-IL-5R are characterised by high sputum eosinophil counts at baseline. Thorax. 2023 Nov;78(11):1138-41.[Abstract][Full Text]
219. Yan K, Balijepalli C, Sharma R, et al. Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis. Immunotherapy. 2019 Dec;11(17):1491-505.[Abstract]
220. Bleecker ER, FitzGerald JM, Chanez P, et al; SIROCCO Study Investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta-2 agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):2115-27.[Abstract]
221. FitzGerald JM, Bleecker ER, Nair P, et al; CALIMA Study Investigators. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):2128-41.[Abstract]
222. Nair P, Wenzel S, Rabe KF, et al; ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017 Jun 22;376(25):2448-58.[Abstract][Full Text]
223. Harrison TW, Chanez P, Menzella F, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2021 Mar;9(3):260-74.[Abstract]
224. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018 Jun 28;378(26):2486-96.[Abstract][Full Text]
225. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66.[Abstract][Full Text]
226. Agache I, Song Y, Rocha C, et al. Efficacy and safety of treatment with dupilumab for severe asthma: a systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. Allergy. 2020 May;75(5):1058-68.[Abstract][Full Text]
227. Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med. 2022 Jan;10(1):11-25.[Abstract]
228. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017 Sep 7;377(10):936-46.[Abstract][Full Text]
229. Chan R, Stewart K, Misirovs R, et al. Targeting downstream type 2 cytokines or upstream epithelial alarmins for severe asthma. J Allergy Clin Immunol Pract. 2022 Feb 5 [Epub ahead of print].[Abstract][Full Text]
230. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021 May 13;384(19):1800-9.[Abstract]
231. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023 Jul 1;208(1):13-24.[Abstract][Full Text]
232. Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med. 2022 Jul;10(7):650-60.[Abstract]
233. Menzies-Gow A, Wechsler ME, Brightling CE, et al. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med. 2023 May;11(5):425-38.[Abstract]
234. Ando K, Fukuda Y, Tanaka A, et al. Comparative efficacy and safety of tezepelumab and other biologics in patients with inadequately controlled asthma according to thresholds of type 2 inflammatory biomarkers: a systematic review and network meta-analysis. Cells. 2022 Feb 26;11(5):819.[Abstract][Full Text]
235. Shaban Abdelgalil M, Ahmed Elrashedy A, Awad AK, et al. Safety and efficacy of tezepelumab vs. placebo in adult patients with severe uncontrolled asthma: a systematic review and meta-analysis. Sci Rep. 2022 Dec 3;12(1):20905.[Abstract][Full Text]
236. Feist J, Lipari M, Kale-Pradhan P. Tezepelumab in the treatment of uncontrolled severe asthma. Ann Pharmacother. 2023 Jan;57(1):62-70.[Abstract]
237. Menzies-Gow A, Steenkamp J, Singh S, et al. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. J Med Econ. 2022 Jan-Dec;25(1):679-90.[Abstract][Full Text]
238. Bourdin A, Brusselle G, Couillard S, et al. Phenotyping of severe asthma in the era of broad-acting anti-asthma biologics. J Allergy Clin Immunol Pract. 2024 Apr;12(4):809-23.[Abstract][Full Text]
239. Mansur AH, Gonem S, Brown T, et al. Biologic therapy practices in severe asthma; outcomes from the UK severe asthma Registry and survey of specialist opinion. Clin Exp Allergy. 2022 Sep 3.[Abstract][Full Text]
240. Asthma and Lung UK. Biologic therapies for severe asthma. May 2025 [internet publication].[Full Text]
241. Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022 Jan;10(1):47-58.[Abstract][Full Text]
242. Jackson DJ, Heaney LG, Humbert M, et al. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet. 2024 Jan 20;403(10423):271-81.[Abstract][Full Text]
243. Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol. 2014 Mar;133(3):921-3.[Abstract]
244. Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017 Jul;140(1):162-9.e2.[Abstract]
245. Moore WC, Kornmann O, Humbert M, et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur Respir J. 2022 Jan;59(1):2100396.[Abstract]
246. Korn S, Bourdin A, Chupp G, et al. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years. J Allergy Clin Immunol Pract. 2021 Dec;9(12):4381-92.e4.[Abstract]
247. Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019 May;143(5):1742-51.e7.[Abstract]
248. Busby J, Khoo E, Pfeffer PE, et al. The effects of oral corticosteroids on lung function, type-2 biomarkers and patient-reported outcomes in stable asthma: a systematic review and meta-analysis. Respir Med. 2020 Nov;173:106156.[Abstract]
249. Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010 Jan 15;181(2):116-24.[Abstract][Full Text]
250. Wahidi MM, Kraft M. Bronchial thermoplasty for severe asthma. Am J Respir Crit Care Med. 2012 Apr 1;185(7):709-14.[Abstract][Full Text]
251. Torrego A, Solà I, Munoz AM, et al. Bronchial thermoplasty for moderate or severe persistent asthma in adults. Cochrane Database Syst Rev. 2014 Mar 3;(3):CD009910.[Abstract][Full Text]
252. Chaudhuri R, Rubin A, Sumino K, et al. Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials. Lancet Respir Med. 2021 May;9(5):457-66.[Abstract]
253. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018 May 17;378(20):1865-76.[Abstract][Full Text]
254. Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019 May 23;380(21):2020-30.[Abstract][Full Text]
255. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 Sep 22;365(12):1088-98.[Abstract][Full Text]
256. Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015 Aug;70(8):748-56.[Abstract][Full Text]
257. Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016 Oct;4(10):781-96.[Abstract]
258. Korenblat P, Sher E, Berman G, et al. P069 effect of lebrikizumab on lung function in patients with severe eosinophilic asthma. Ann Allergy Asthma Immunol. 2021 Nov 1;127(5):S34.[Full Text]
259. Corren J, Szefler SJ, Sher E, et al. Lebrikizumab in uncontrolled asthma: reanalysis in a well-defined type 2 population. J Allergy Clin Immunol Pract. 2024 May;12(5):1215-24.e3.[Abstract][Full Text]
260. Szefler SJ, Roberts G, Rubin AS, et al. Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS). Clin Transl Allergy. 2022 Jul;12(7):e12176.[Abstract][Full Text]
261. Kosloski MP, Kalliolias GD, Xu CR, et al. Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials. Clin Transl Sci. 2022 Feb;15(2):384-95.[Abstract][Full Text]
262. Xu C, Xin K, Kosloski MP, et al. Pharmacokinetics of subcutaneous itepekimab injection with an autoinjector device and prefilled syringe in healthy participants. Clin Pharmacol Drug Dev. 2024 Nov;13(11):1181-8.[Abstract][Full Text]
263. Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med. 2021 Oct 28;385(18):1656-68.[Abstract][Full Text]
264. Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021 Nov;9(11):1288-98.[Abstract]
265. Jackson DJ, Wechsler ME, Jackson DJ, et al. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. N Engl J Med. 2024 Dec 19;391(24):2337-49.[Abstract]
266. Davidescu L, Ursol G, Korzh O, et al. Efficacy and safety of masitinib in corticosteroid-dependent severe asthma: a randomized placebo-controlled trial. J Asthma Allergy. 2022;15:737-47.[Abstract][Full Text]
267. Park C, Jang JH, Kim C, et al. Real-world effectiveness of statin therapy in adult asthma. J Allergy Clin Immunol Pract. 2024 Feb;12(2):399-408.e6.[Abstract]
268. Naing C, Ni H. Statins for asthma. Cochrane Database Syst Rev. 2020 Jul 15;7(7):CD013268.[Abstract][Full Text]
269. Sunata K, Kabata H, Kuno T, et al. The effect of statins for asthma. A systematic review and meta-analysis. J Asthma. 2022 Apr;59(4):801-10.[Abstract]
270. Alabed M, Elemam NM, Ramakrishnan RK, et al. Therapeutic effect of statins on airway remodeling during asthma. Expert Rev Respir Med. 2022 Jan;16(1):17-24.[Abstract][Full Text]
271. Zhang QX, Zhang HF, Lu XT, et al. Statins improve asthma symptoms by suppressing inflammation: a meta-analysis based on RCTs. Eur Rev Med Pharmacol Sci. 2022 Nov;26(22):8401-10.[Abstract][Full Text]
272. Althoff MD, Gaietto K, Holguin F, et al. Obesity-related asthma: a pathobiology-based overview of existing and emerging treatment approaches. Am J Respir Crit Care Med. 2024 Nov 15;210(10):1186-200.[Abstract][Full Text]
273. Lee B, Man KKC, Wong E, et al. Antidiabetic medication and asthma attacks. JAMA Intern Med. 2025 Jan 1;185(1):16-25.[Abstract]
274. Rao R, Mei J, Chen H, et al. Association of metformin use with asthma development and adverse outcomes: a systematic review and meta-analysis. Medicine (Baltimore). 2024 Oct 4;103(40):e39785.[Abstract][Full Text]
275. Rogliani P, Calzetta L, Capuani B, et al. Glucagon-like peptide 1 receptor: a novel pharmacological target for treating human bronchial hyperresponsiveness. Am J Respir Cell Mol Biol. 2016 Dec;55(6):804-14.[Abstract][Full Text]
276. Foer D, Beeler PE, Cui J, et al. Asthma exacerbations in patients with type 2 diabetes and asthma on glucagon-like peptide-1 receptor agonists. Am J Respir Crit Care Med. 2021 Apr 1;203(7):831-40.[Abstract][Full Text]
277. Viby NE, Isidor MS, Buggeskov KB, et al. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. 2013 Dec;154(12):4503-11.[Abstract]
278. Bloodworth MH, Rusznak M, Pfister CC, et al. Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virus-induced type 2 responses and immunopathology. J Allergy Clin Immunol. 2018 Aug;142(2):683-7.e12.[Abstract][Full Text]
279. Toki S, Goleniewska K, Reiss S, et al. Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo. J Allergy Clin Immunol. 2018 Nov;142(5):1515-28.e8.[Abstract][Full Text]
280. Gurgel RK, Baroody FM, Damask CC, et al. Clinical practice guideline: immunotherapy for inhalant allergy. Otolaryngol Head Neck Surg. 2024 Mar;170(suppl 1):S1-42.[Abstract]
281. Toward Optimized Practice (Alberta Doctors). Chronic asthma. April 2018 [internet publication].[Full Text]
282. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020 Jan 2;55(1):1900588.[Abstract][Full Text]
283. Agache I, Lau S, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: house dust mite-driven allergic asthma. Allergy. 2019 May;74(5):855-73.[Abstract][Full Text]
284. Smith D, Du Rand I, Addy CL, et al. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. Thorax. 2020 May;75(5):370-404.[Abstract][Full Text]
285. Tupper OD, Andersen ZJ, Ulrik CS. Demographic, lifestyle and comorbid risk factors for all-cause mortality in a Danish cohort of middle-aged adults with incident asthma. BMJ Open. 2021 Oct 4;11(10):e049243.[Abstract][Full Text]
286. Lommatzsch M, Buhl R, Canonica GW, et al. Pioneering a paradigm shift in asthma management: remission as a treatment goal. Lancet Respir Med. 2024 Feb;12(2):96-9.[Abstract]
287. Shackleford A, Heaney LG, Redmond C, et al. Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis. Lancet Respir Med. 2025 Jan;13(1):23-34.[Abstract][Full Text]
288. Blaiss M, Oppenheimer J, Corbett M, et al. Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment. Ann Allergy Asthma Immunol. 2023 Dec;131(6):782-5.[Abstract]
289. Slade DJ, Kraft M. Airway remodeling from bench to bedside: current perspectives. Clin Chest Med. 2006 Mar;27(1):71-85.[Abstract]
290. Mascia K, Haselkorn T, Deniz YM, et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2005 Nov;116(5):970-5.[Abstract]
291. Chalitsios CV, Shaw DE, McKeever TM. Risk of osteoporosis and fragility fractures in asthma due to oral and inhaled corticosteroids: two population-based nested case-control studies. Thorax. 2021 Jan;76(1):21-8.[Abstract][Full Text]
292. Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193-204.[Abstract]
293. Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. BMJ. 2021 Jul 12;374:n1380.[Abstract]
294. Heatley H, Tran TN, Bourdin A, et al. Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma. Thorax. 2023 Sep;78(9):860-7.[Abstract][Full Text]
295. Dhippayom T, Wateemongkollert A, Mueangfa K, et al. Comparative efficacy of strategies to support self-management in patients with asthma: a systematic review and network meta-analysis. J Allergy Clin Immunol Pract. 2022 Mar;10(3):803-14.[Abstract]
296. Alexandre-Sousa P, Sousa N, Bento J, et al. Nurses' role in the control and treatment of asthma in adults: a systematic literature Rreview. Adv Respir Med. 2024 Apr 25;92(3):175-89.[Abstract][Full Text]
297. Nelsen LM, Kosinski M, Rizio AA, et al. A structured review evaluating content validity of the Asthma Control Test, and its consistency with U.S. guidelines and patient expectations for asthma control. J Asthma. 2022 Mar;59(3):628-37.[Abstract]
298. Chu F, Kappel N, Akel M, et al. Validity of the childhood asthma control test in diverse populations: a systematic review. Pediatr Pulmonol. 2023 May;58(5):1322-36.[Abstract]
299. Bansal A, Franklin L, Twohig H. Optimising inhaled therapy for patients with asthma. BMJ. 2024 Sep 20;386:e080353.
300. Kang HQ, Pen Y, He Y, et al. The experience of shared decision-making for people with asthma: a systematic review and metasynthesis of qualitative studies. Health Expect. 2024 Apr;27(2):e14039.[Abstract][Full Text]
301. Kew KM, Malik P, Aniruddhan K, et al. Shared decision-making for people with asthma. Cochrane Database Syst Rev. 2017 Oct 3;10(10):CD012330.[Abstract][Full Text]
302. Gatheral TL, Rushton A, Evans DJ, et al. Personalised asthma action plans for adults with asthma. Cochrane Database Syst Rev. 2017 Apr 10;4(4):CD011859.[Abstract][Full Text]
303. Riley IL, Jackson B, Crabtree D, et al. A scoping review of international barriers to asthma medication adherence mapped to the theoretical domains framework. J Allergy Clin Immunol Pract. 2021 Jan;9(1):410-8.e4.[Abstract]
304. van de Hei SJ, Dierick BJH, Aarts JEP, et al. Personalized medication adherence management in asthma and chronic obstructive pulmonary disease: a review of effective interventions and development of a practical adherence toolkit. J Allergy Clin Immunol Pract. 2021 Nov;9(11):3979-94.[Abstract][Full Text]
305. Monteiro C, Maricoto T, Prazeres F, et al. Determining factors associated with inhaled therapy adherence on asthma and COPD: a systematic review and meta-analysis of the global literature. Respir Med. 2022 Jan;191:106724.[Abstract][Full Text]
306. Visser CD, Antonisse LLM, Alleda FM, et al. Self-management support with the respiratory adherence care enhancer instrument in asthma and chronic obstructive pulmonary disease: an implementation trial. Br J Clin Pharmacol. 2024 May;90(5):1344-56.[Abstract][Full Text]
307. Chan A, De Simoni A, Wileman V, et al. Digital interventions to improve adherence to maintenance medication in asthma. Cochrane Database Syst Rev. 2022 Jun 13;6(6):CD013030.[Abstract][Full Text]
308. Sunjaya AP, Ansari S, Jenkins CR. A systematic review on the effectiveness and impact of clinical decision support systems for breathlessness. NPJ Prim Care Respir Med. 2022 Aug 20;32(1):29.[Abstract][Full Text]
309. Chongmelaxme B, Chaiyakunapruk N, Dilokthornsakul P. Association between adherence and severe asthma exacerbation: a systematic review and meta-analysis. J Am Pharm Assoc (2003). 2020 Sep-Oct;60(5):669-85.e2.[Abstract]
310. Kinley E, Skene I, Steed E, et al. Delivery of supported self-management in remote asthma reviews: a systematic rapid realist review. Health Expect. 2022 Aug;25(4):1200-14.[Abstract][Full Text]
311. McTague K, Prizeman G, Shelly S, et al. Youths with asthma and their experiences of self-management education: a systematic review of qualitative evidence. J Adv Nurs. 2022 Dec;78(12):3987-4002.[Abstract][Full Text]
312. Hale EM, Greene G, Mulvey C, et al. Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial. Lancet Respir Med. 2023 Jul;11(7):591-601.[Abstract]
313. Almutairi M, Marriott JF, Mansur A. Effect of monitoring adherence to regular inhaled corticosteroid (ICS) alone or in combination with a long-acting beta2-agonist (LABA) using electronic methods on asthma outcomes: a narrative systematic review. BMJ Open. 2023 Aug 16;13(8):e074127.[Abstract][Full Text]
314. Chongmelaxme B, Lee S, Dhippayom T, et al. The effects of telemedicine on asthma control and patients' quality of life in adults: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2019 Jan;7(1):199-216.[Abstract]
315. Jeminiwa R, Hohmann L, Qian J, et al. Impact of eHealth on medication adherence among patients with asthma: a systematic review and meta-analysis. Respir Med. 2019 Mar;149:59-68.[Abstract][Full Text]
316. Unni E, Gabriel S, Ariely R. A review of the use and effectiveness of digital health technologies in patients with asthma. Ann Allergy Asthma Immunol. 2018 Dec;121(6):680-91.[Abstract][Full Text]
317. Song X, Hallensleben C, Zhang W, et al. Blended self-management interventions to reduce disease burden in patients with chronic obstructive pulmonary disease and asthma: systematic review and meta-analysis. J Med Internet Res. 2021 Mar 31;23(3):e24602.[Abstract][Full Text]
318. Murphy J, McSharry J, Hynes L, et al. Prevalence and predictors of adherence to inhaled corticosteroids in young adults (15-30 years) with asthma: a systematic review and meta-analysis. J Asthma. 2021 May;58(5):683-705.[Abstract]
319. Busby J, McDowell PJ, Pfeffer PE, et al. Ethnic variation in asthma phenotypic presentation and outcomes: a cross-sectional analysis of the UK Biobank. Thorax. 2024 Jan 18;79(2):186-90.[Abstract][Full Text]
320. Israel E, Cardet JC, Carroll JK, et al. Reliever-triggered inhaled glucocorticoid in black and Latinx adults with asthma. N Engl J Med. 2022 Apr 21;386(16):1505-18.[Abstract][Full Text]
321. Roche N, Aggarwal B, Boucot I, et al. The impact of inhaler technique on clinical outcomes in adolescents and adults with asthma: a systematic review. Respir Med. 2022 Oct;202:106949.[Abstract][Full Text]
322. Abdelrahman MA, Saeed H, Osama H, et al. Effect of verbal counselling on metred-dose inhaler proper use and lung function test amongst asthmatic patients: a meta-analysis. Int J Clin Pract. 2021 Jun;75(6):e14077.[Abstract]
323. Rodriguez-Garcia C, Barreiro E, Muñoz-Gall X, et al. Common errors in inhalation therapy: Impact and solutions. Clin Respir J. 2020 Nov;14(11):1001-10.[Abstract][Full Text]
324. Murphy AC, Carroll W, Gotsell M, et al. How do patients determine when their inhaler is empty? Insights from an analysis of returned inhalers and a patient survey. BMJ Open Respir Res. 2024 Dec 25;11(1):e002579.[Abstract][Full Text]
325. Jia X, Zhou S, Luo D, et al. Effect of pharmacist-led interventions on medication adherence and inhalation technique in adult patients with asthma or COPD: a systematic review and meta-analysis. J Clin Pharm Ther. 2020 Oct;45(5):904-17.[Abstract][Full Text]
326. Saleem SS, Khan A, Aman R, et al. Impact of pharmacist-led educational intervention on knowledge of self-management among asthmatic patients: a prospective cohort study. BMJ Open. 2022 Jun 15;12(6):e058861.[Abstract][Full Text]
327. Ten Have P, van Hal P, Wichers I, et al. Turning green: the impact of changing to more eco-friendly respiratory healthcare - a carbon and cost analysis of Dutch prescription data. BMJ Open. 2022 Jun 14;12(6):e055546.[Abstract]
328. Wilkinson AJK, Maslova E, Janson C, et al. Greenhouse gas emissions associated with suboptimal asthma care in the UK: the SABINA healthCARe-Based envirONmental cost of treatment (CARBON) study. Thorax. 2024 Feb 27;79(5):412-21.[Abstract][Full Text]
329. Woodcock A, Janson C, Rees J, et al. Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis. Thorax. 2022 Dec;77(12):1187-92.[Abstract][Full Text]
330. Usmani OS, Bosnic-Anticevich S, Dekhuijzen R, et al. Real-world impact of nonclinical inhaler regimen switches on asthma or COPD: a systematic review. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2624-37.[Abstract][Full Text]
331. Landré B, Nadif R, Goldberg M, et al. Asthma is associated with frailty among community-dwelling adults: the GAZEL cohort. BMJ Open Respir Res. 2020 Feb;7(1):e000526.[Abstract][Full Text]
332. Skloot GS, Busse PJ, Braman SS, et al. An official American Thoracic Society workshop report: evaluation and management of asthma in the elderly. Ann Am Thorac Soc. 2016 Nov;13(11):2064-77.[Abstract][Full Text]
333. Lee C, Alexander E, Lee R, et al. Behavioral interventions for asthma self-management in South Asian populations: a systematic review. J Asthma. 2021 Jan;58(1):112-20.[Abstract]
334. Henneberger PK, Patel JR, de Groene GJ, et al. Workplace interventions for treatment of occupational asthma. Cochrane Database Syst Rev. 2019 Oct 8;10(10):CD006308.[Abstract][Full Text]
335. Healthcare Quality Improvement Partnership. Breathing well respiratory audit report (NRAP). Jul 2024 [internet publication].[Full Text]
336. Cooper M, Park-Lee E, Ren C, et al. Notes from the field: E-cigarette use among middle and high school students - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Oct 7;71(40):1283-5.[Full Text]
337. Barnes C, Turon H, McCrabb S, et al. Interventions to prevent or cease electronic cigarette use in children and adolescents. Cochrane Database Syst Rev. 2023 Nov 15;11(11):CD015511.[Abstract][Full Text]
338. Quirce S, Domínguez-Ortega J, Luna JA. Novel approaches in occupational asthma diagnosis and management. Curr Opin Pulm Med. 2021 Jan;27(1):9-14.[Abstract]
339. Leas BF, D'Anci KE, Apter AJ, et al. Effectiveness of indoor allergen reduction in asthma management: a systematic review. J Allergy Clin Immunol. 2018 May;141(5):1854-69.[Abstract][Full Text]
340. Vazquez-Ortiz M, Angier E, Blumchen K, et al. Understanding the challenges faced by adolescents and young adults with allergic conditions: a systematic review. Allergy. 2020 Aug;75(8):1850-80.[Abstract][Full Text]
341. Cooley C, Park Y, Ajilore O, et al. Impact of interventions targeting anxiety and depression in adults with asthma. J Asthma. 2022 Feb;59(2):273-87.[Abstract][Full Text]
342. Tran L, Sharrad K, Kopsaftis Z, et al. Pharmacological interventions for the treatment of psychological distress in patients with asthma: a systematic review and meta-analysis. J Asthma. 2021 Jun;58(6):759-69.[Abstract]
343. Nebati E. Do psychological interventions improve outcomes for asthma in children and young people? Clin Exp Allergy. 2024 May;54(5):311-3.[Abstract][Full Text]
344. Sharrad KJ, Sanwo O, Cuevas-Asturias S, et al. Psychological interventions for asthma in children and adolescents. Cochrane Database Syst Rev. 2024 Jan 11;1(1):CD013420.[Abstract][Full Text]
345. Ji Z, López-de-Andrés A, Jiménez-García R, et al. Mental health in patients with asthma: A population-based case-control study. Respir Med. 2022 Mar;193:106758.[Abstract][Full Text]
346. Zhang Y, Cheng J, Li Y, et al. Suicidality among patients with asthma: a systematic review and meta-analysis. J Affect Disord. 2019 Sep 1;256:594-603.[Abstract]
347. Tyson L, Hardeman W, Marquette M, et al. A systematic review of the characteristics of interventions that promote physical activity in adults with asthma. J Health Psychol. 2022 Oct;27(12):2777-96.[Abstract][Full Text]
348. Valkenborghs SR, Anderson SL, Scott HA, et al. Exercise training programs improve cardiorespiratory and functional fitness in adults with asthma: a systemic review and meta-analysis. J Cardiopulm Rehabil Prev. 2022 Nov 1;42(6):423-33.[Abstract]
349. Holland AE, Spathis A, Marsaa K, et al. European Respiratory Society clinical practice guideline on symptom management for adults with serious respiratory illness. Eur Respir J. 2024 Jun 28;63(6):2400335.[Abstract][Full Text]
350. Santino TA, Chaves GS, Freitas DA, et al. Breathing exercises for adults with asthma. Cochrane Database Syst Rev. 2020 Mar 25;(3):CD001277.[Abstract][Full Text]
351. Nyenhuis SM, Kahwash B, Cooke A, et al. Recommendations for physical activity in asthma: a work group report of the AAAAI Sports, Exercise, and Fitness Committee. J Allergy Clin Immunol Pract. 2022 Feb;10(2):433-43.[Abstract]
352. Kahwash BM, Gregory KL, Sharp LK, et al. Results from a national survey of asthma provider beliefs and practices regarding exercise and asthma: a work group report of the AAAAI Committee on Sports, Exercise, and Fitness. J Allergy Clin Immunol Pract. 2022 Jul;10(7):1778-83.[Abstract][Full Text]
353. Kuder MM, Clark M, Cooley C, et al. A systematic review of the effect of physical activity on asthma outcomes. J Allergy Clin Immunol Pract. 2021 Sep;9(9):3407-21.e8.[Abstract][Full Text]
354. McLoughlin RF, Clark VL, Urroz PD, et al. Increasing physical activity in severe asthma: a systematic review and meta-analysis. Eur Respir J. 2022 Dec;60(6):2200546.[Abstract]
355. Li X, Mao C, Pan Y. Effect of routine therapy assisted by physical exercise on pulmonary function in patients with asthma in stable stage: a systematic review and meta-analysis of randomized clinical trials. Comput Math Methods Med. 2022;2022:2350297.[Abstract][Full Text]
356. Man W, Chaplin E, Daynes E, et al. British Thoracic Society clinical statement on pulmonary rehabilitation. Thorax. 2023 Oct;78(suppl 4):s2-15.[Full Text]
357. Garagorri-Gutiérrez D, Leirós-Rodríguez R. Effects of physiotherapy treatment in patients with bronchial asthma: a systematic review. Physiother Theory Pract. 2022 Apr;38(4):493-503.[Abstract][Full Text]
358. Osadnik CR, Gleeson C, McDonald VM, et al. Pulmonary rehabilitation versus usual care for adults with asthma. Cochrane Database Syst Rev. 2022 Aug 22;8(8):CD013485.[Abstract][Full Text]
359. Okoniewski W, Lu KD, Forno E. Weight loss for children and adults with obesity and asthma: a systematic review of randomized controlled trials. Ann Am Thorac Soc. 2019 May;16(5):613-25.[Abstract][Full Text]
360. Hossain N, Arhi C, Borg CM. Is bariatric surgery better than nonsurgical weight loss for improving asthma control? A Systematic Review. Obes Surg. 2021 Apr;31(4):1810-32.[Abstract]
361. Lazarinis N, Jørgensen L, Ekström T, et al. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax. 2014 Feb;69(2):130-6.[Abstract][Full Text]
362. Centers for Disease Control and Prevention. Vaccines & Immunizations: adult immunization schedule by age (addendum updated July 2, 2025); recommendations for ages 19 years or older, United States, 2025. Jul 2025 [internet publication].[Full Text]
363. Centers for Disease Control and Prevention. Vaccines & immunizations: child and adolescent immunization schedule by age (addendum updated July 2, 2025). Jul 2025 [internet publication].[Abstract][Full Text]
364. Fortescue R, Kew KM, Leung MST. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. 2020 Sep 14;(9):CD011293.[Abstract][Full Text]
365. Kappen J, Diamant Z, Agache I, et al. Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: an EAACI position paper. Allergy. 2023 Nov;78(11):2835-50.[Abstract][Full Text]
366. Novakova P, Tiotiu A, Baiardini I, et al. Allergen immunotherapy in asthma: current evidence. J Asthma. 2021 Feb;58(2):223-30.[Abstract][Full Text]
367. Hoof I, Bønnelykke K, Stranzl T, et al. Genetic and T2 biomarkers linked to the efficacy of HDM sublingual immunotherapy in asthma. Thorax. 2024 Mar 15;79(4):332-9.[Abstract][Full Text]
368. Cooper M, Park-Lee E, Ren C, et al. Notes from the ield: E-cigarette use among middle and high school students - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Oct 7;71(40):1283-5.[Abstract][Full Text]
